Sareum Holdings


Market Cap£125m

Last Close 3.65p

Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its pre-clinical TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is undergoing advanced dose finding and toxicology studies with a target to file a CTA in mid-2021. Other programmes include the CHK1 inhibitor SRA737, out licensed to Sierra Oncology (Sareum holds a 27.5% stake of the economics of the licence agreement) and the de-prioritised FLT3+Aurora kinase.

More Sareum Holdings content >

Investment summary

On 9 September 2022 the US FDA approved Bristol Myers Squibb’s first-in-class tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) for the treatment of moderate-to-severe plaque psoriasis in adults, making it the first selective TYK2 inhibitor to be approved for any indication. We expect this news to have a positive read-across for Sareum Holdings’ lead asset, SDC-1801, a dual TYK2/JAK 1 inhibitor. As a reminder, Sareum recently announced the filing of a clinical trial authorisation application for SDC-1801 with the UK Medicines and Healthcare products Regulatory Agency. The Phase Ia (in healthy subjects) is planned to start in Q4 CY22, and a Phase Ib (in psoriasis patients) is planned to start in CY23 subject to regulatory approval. The approval of Sotyktu was widely expected and validates the potential of this new asset class, in our opinion. Sareum asserts that SDC-1801’s dual targeting could potentially accord superior efficacy, which if proved could translate to a sizeable market opportunity for Sareum.

Content on Sareum Holdings
Sareum Holdings – Sotyktu approval positive read-across for SDC-1801
Healthcare | research Flash note | 13 September 2022
Sareum Holdings – SDC-1801 CTA filed in the UK
Healthcare | research Flash note | 29 July 2022
Sareum Holdings – GSK’s Sierra acquisition, read-across for Sareum
Healthcare | research Flash note | 14 April 2022
View more
Register to receive research on Sareum Holdings as it is published
Share price graph
Price performance
Actual (8.8) (36.0) 111.6
Relative* (9.4) (36.0) 92.4
52-week high/low 9.2p/1.5p
*% relative to local index
Key management
Tim Mitchell CEO
John Reader CSO
Stephen Parker Non-executive chairman